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The effect of total and partial nephrectomy on the pharmacokinetics of 
intravenous paracetamol in humans 
Abstract 
Paracetamol is one of the most common analgesic and antipyretic drugs. Recently intravenous 
paracetamol has been widely used to treat moderate postoperative pain. Surgery is the main method of 
treatment of renal cancer. Total or partial nephrectomy can be performed, depending on the size and 
location of the tumor. Pharmacokinetics of drugs may depend on the type of surgery. The aim of the 
study was to compare the postinfusion pharmacokinetics of paracetamol in patients after total 
nephrectomy (TN) and nephron sparing surgery (NSS).The research was carried out on two groups of 
patients after nephrectomy: total (TN n = 37; mean [SD], age, 60.4 [10.9] years; BMI, 26.5 [3.8] kg/m2; 
creatinine clearance, Cl, 80.9 [37.1] mL/min) and nephron sparing surgery (NSS n = 17; 57.9 [16.5] years; 
BMI, 29.5 [5.3] kg/m2; Cl, 97.6 [27.8] mL/min). The patients were treated with paracetamol (PerfalganO 
Bristol-Myers Squibb) at an intravenous dose of 1.000 mg, which was infused for 15 minutes after 
surgery. The concentrations of paracetamol in the patients' plasma were determined by the HPLC method 
with UV detection (X = 261 run). The main pharmacokinetic parameters of paracetamol in the TN vs. NSS 
group were as follows: C.. 29.08 [17.39] vs. 27.54 [15.70] pg/mL (p = 0.6692); AUC5, 29.24 [13.86] vs. 
34.85 [14.28] pg.h/mL (p = 0.2896); AUMC5,,,, 47.58 [26.08] vs. 62.02 [27.64] pg-h/mL (p = 0.1345); to. 
2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively. In both groups the exposure to paracetamol was 
comparable. The t1/2 after nephron sparing surgery was shorter than after total nephrectomy. Therefore, 
these patients may demand more frequent drug administration. In the NSS group the C. of the analgesic 
was considerably reduced in men. 
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Patients undergoing nephrectomy are a special
group, because their pharmacokinetic (PK) parame-
ters may be different than in healthy patients. Drug
PK may also depend on the type of surgery. Partial
kidney resection may have different influence on PK
parameters than total kidney resection. NSS has
minimal influence on the glomerular filtration rate,
whereas total nephrectomy reduces creatinine clear-
ance (1, 2). Monitoring PK parameters in these
patients would enable precise dosage. The aim of
therapeutic drug monitoring (TDM) is to measure
the drug concentration in the patientís blood and
adjust dosage to their individual needs so as to make
the therapy effective and to cause as few adverse
reactions as possible. The concomitance of diseases
which changes PK and polypharmacy is an indica-
tion for TDM. This situation can be observed in
patients after kidney resection.
Paracetamol is one of the most common anal-
gesics and antipyretics applied in inpatient and out-
patient health care. In recent years special attention
has been given to the intravenous form of paraceta-
mol, which guarantees a quick and efficacious ther-
apeutic effect. It is more and more widely used for
treatment of moderate pain, especially in the post-
operative period in intensive care units and depart-
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Abstract: Paracetamol is one of the most common analgesic and antipyretic drugs. Recently intravenous parac-
etamol has been widely used to treat moderate postoperative pain. Surgery is the main method of treatment of
renal cancer. Total or partial nephrectomy can be performed, depending on the size and location of the tumor.
Pharmacokinetics of drugs may depend on the type of surgery. The aim of the study was to compare the postin-
fusion pharmacokinetics of paracetamol in patients after total nephrectomy (TN) and nephron sparing surgery
(NSS). The research was carried out on two groups of patients after nephrectomy: total (TN n = 37; mean [SD],
age, 60.4 [10.9] years; BMI, 26.5 [3.8] kg/m2; creatinine clearance, Clcr, 80.9 [37.1] mL/min) and nephron spar-
ing surgery (NSS n = 17; 57.9 [16.5] years; BMI, 29.5 [5.3] kg/m2; Clcr, 97.6 [27.8] mL/min). The patients were
treated with paracetamol (PerfalganÆ, Bristol-Myers Squibb) at an intravenous dose of 1.000 mg, which was
infused for 15 minutes after surgery. The concentrations of paracetamol in the patientsí plasma were determined
by the HPLC method with UV detection (λ = 261 nm). The main pharmacokinetic parameters of paracetamol
in the TN vs. NSS group were as follows: Cmax 29.08 [17.39] vs. 27.54 [15.70] µg/mL (p = 0.6692); AUC5stop-t
29.24 [13.86] vs. 34.85 [14.28] µg∑h/mL (p = 0.2896); AUMC5stop-t 47.58 [26.08] vs. 62.02 [27.64] µg∑h2/mL (p
= 0.1345); t0.5 2.34 [0.96] vs. 1.93 [0.50] h (p = 0.1415), respectively. In both groups the exposure to paraceta-
mol was comparable. The t1/2 after nephron sparing surgery was shorter than after total nephrectomy. Therefore,
these patients may demand more frequent drug administration. In the NSS group the Cmax of the analgesic was
considerably reduced in men. 
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ments of surgery (3). Apart from the quick effect,
intravenous administration enables elimination of
differences resulting from individually varying rate
of absorption. The biotransformation and excretion
of paracetamol are processes which depend on the
patientís age, activity of hepatic enzymes and renal
function. Acetaminophen is chiefly eliminated in the
form of metabolites, with urine ñ as glucuronate and
sulfate (90-95%), and with bile ñ as cysteinate and
mercaptopurinate (5-10%). About 1-4% of the dose
is eliminated in an unchanged form by kidneys ñ it
is the consequence of the chemical structure of the
compound (4, 5). Paracetamol is only minimally
bound by plasma proteins and it is easily filtrated in
the glomeruli. It is reabsorbed in the distal part of
the nephron. Glucuronates and sulfates are high-
polarity compounds and they are eliminated by kid-
neys in the process of glomerular filtration and tubu-
lar secretion.
The elimination of paracetamol and its metabo-
lites is longer in patients with acute renal failure.
The elimination rate in these patients is three times
slower than in the control group.
It has also been proved that when therapeutic
doses of paracetamol are applied to patients under-
going hemodialysis, t1/2 is reduced by 40-50% (4, 5).
From the clinical point of view it is important to
acquire information how strongly kidney resection
may influence drug elimination.
Apart from total nephrectomy (TN), nephron
sparing surgery (NSS) is increasingly being used to
treat patients with solid renal lesions. The technical
success rate of nephron sparing surgery is excellent
and operative morbidity and mortality are low. For
renal cell carcinoma, long-term cancer-free survival
is comparable to that after radical nephrectomy, par-
ticularly for low-stage disease (6, 7).
In order to obtain this information we scanned
the databases of Medline and PubMed with the fol-
lowing entries: paracetamol, intravenous paraceta-
mol, total and/or partial kidney resection. We found
no publications concerning relations between the PK




Paracetamol, HPLC grade acetonitrile, per-
chloric acid, theophyllinum were purchased from
Sigma-Aldrich (Poland), 85% orthophosphoric acid,
methanol from Merck (Poland), anhydrous sodium
sulfate from Fluka (Poland). Water used in the
mobile phase was deionised, distilled and filtered
through a Millipore system before use. PerfalganÆ
was purchased from Bristol-Myers Squibb Polska
Sp. z o.o., Warsaw, Poland (batch number
1K67394).
Subjects
This study was performed in cooperation with
Urology Clinic, Medical University of GdaÒsk,
(Poland), and at the Department and Unit of Clinical
Pharmacy and Biopharmacy, PoznaÒ University of
Medical Sciences, (Poland). All the described pro-
cedures were reviewed and approved by the
Institutional Review Board at the PoznaÒ University
of Medical Sciences and by the local ethics commit-
tee at the Medical University of GdaÒsk. This study
was conducted in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki
and its later amendments. The study was carried out
on 54 patients (29 men and 25 women), who were
hospitalized for surgical treatment due to renal
tumor. The inclusion criteria were as follows:
patients with renal masses qualified for total or par-
tial nephrectomy; age > 18 years; no history of
allergy to paracetamol; pain greater than 1-3 (VAS;
Visual Analogue Scale); consent to take part in the
research; suitability for surgery; no kidney failure
confirmed by creatinine level and eGFR (estimated
glomerular filtration rate). The research was
explained to the patients, and those who consented
to the drug administration and blood collection were
enrolled as subjects. All the patients gave their
informed consent prior to inclusion in the study. The
exclusion criteria were as follows: previous para-
cetamol exposure, allergy to paracetamol, serious
functional cardiac, kidney and hepatic disorders,
patients with polycystic kidneys, age under 18 years.
Creatinine clearance for each patient was calculated
using the Cockroft-Gault formula from creatinine
concentration value obtained on the day of measure-
ment of paracetamol concentration (2).
Drug administration and blood sampling
Paracetamol was administered to patients in a
single intravenous infusion at the dose of 1000 mg
(100 mL of solution; PerfalganÆ 10 mg/mL,
Bristol-Myers Squibb), on a 1st day after the neph-
rectomy. It was the one and only dose of paraceta-
mol that patients received during the study. The time
of infusion was 15 min. Blood samples were col-
lected immediately before infusion (0í) and after
infusion termination, at the following time points: 5,
15 min and 0.5, 1, 2, 3, 5, 4, 6 h. The blood samples
(1 mL) were transferred into heparinized tubes and
they were centrifuged at 4,000 rpm for 10 min at
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4OC. Next, the plasma was transferred to propylene
tubes and stored at -20OC until analysis.
Drug assay
The concentration of paracetamol was
assayed using the high-performance liquid chro-
matography (HPLC) method with UV-Vis detec-
tion (8). Separation was achieved by isocratic elu-
tion of the mobile phase, sodium sulfate 0.05 M pH
2.2 (adjusted with 85% orthophosphoric acid) ñ
acetonitrile (93 : 7, v/v), at a flow rate of 1.5
mL/min through an ODS HypersilÆ C18 column
(150 mm ◊ 4.6 mm, 5.0 µm particle size) (Thermo
Electron CorporationÆ). The column temperature
was maintained at 25OC, the UVñVis detection
wavelength was set at 261 nm, and the injection
volume was 50 µL. The total analysis time for each
run was 5 min. The lower limit of quantification
(LLOQ) was 0.15 µg/mL. Intra- and inter-day pre-
cision and accuracy of the LLOQ, low quality con-
trol (0.3 µg/mL), medium quality control (30.0
µg/mL), and high quality control (60.0 µg/mL)
were well within the acceptable limit of 10% coef-
ficient of variation (CV%). The calibration for
paracetamol was linear, ranging within 0.15-75.0
µg/mL (r = 0.999).
Pharmacokinetics and statistics
Pharmacokinetic calculations were based on
non-compartmental analysis using PhoenixÆ
WinNonlinÆ 6.4 software (Certara L.P., US). Since the
obtained data do not permit the calculation of a two-
compartment model, non-compartmental analysis was
conducted. Pharmacokinetics calculation were based
on the postinfusion pharmacokinetics. The following
pharmacokinetic parameters were calculated for
paracetamol: elimination rate constant (kel), area under
the plasma concentration-time curve from 5 min after
infusion termination to infinity (AUC5min-inf), area
under the plasma concentration-time curve from 5
minutes after infusion termination to the time of last
measurable concentration (AUC5min-t); maximum
observed plasma concentration (Cmax), time to first
occurrence of Cmax (tmax), half-life in elimination phase
(t1/2), clearance (Cl), volume of distribution (Vd), area
under the first moment curve measured between 5 min
after infusion termination to the last measurable con-
centration (AUMC5min-t), mean residence time
(MRT5min-t). The elimination half-life (t1/2) was calcu-
lated with the last 4 points of the curve. The maximum
plasma concentration (Cmax) and the time to reach the
maximum plasma concentration (tmax) were obtained
directly from the concentration ñ time data.
Figure 1. The mean paracetamol plasma concentration vs. time profiles following a single 1.000 mg intravenous dose in the patients after
total nephrectomy (TN) and nephron sparing surgery (NSS)
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Statistical analysis
Statistical calculations were made with SAS
software package (SAS Institute Inc. 2002-2010.
The SAS System for Windows version 9.3. Cary,
NC, USA). Two-way analysis of variance was used
to estimate statistical significance of differences
between the results obtained in the NSS and TN
groups and between men and woman (PROC GLM).
The paracetamol Cl and MRT5min-t was correlated
with creatinine clearance (Clcr), eGFR, creatinine
level (Ccr) (after surgery) at baseline using linear
correlation analysis (Pearson correlation coefficient
provided). Studentís t-test was used to estimate sta-
tistical significance of differences between the
results obtained in the groups of men and women
within the treatment groups. The 90% confidence
intervals for the ratio of geometric means were con-
structed for the treatment groups to evaluate bio-
equivalence.
RESULTS
Fifty-four subjects (29 men, 25 women; 32-86
years of age) were enrolled in and completed the
research (first subjectís visit: 11 May 2011; last sub-
jectís visit: 4 April 2013). Patients were divided into
two groups: patients after total nephrectomy (TN)
and after NSS. TN group consisted of 22 men and 15
women, while NSS group included 7 men and 10
women with average age [years] (S ± SD) 60.35 ±
10.95 and 57.88 ± 16.48, weight [kg] 79.66 ± 13.17
and 82.35 ± 15.70, height [m] 1.73 ± 0.08 and 1.69
± 0.08, BMI [kg/m2] 26.51 ± 3.81 and 29.47 ± 5.26,
respectively. Mean parameters used to assess renal
function were as follows: BUN [mg/dL] 17.79 ±
5.86 and 16.59 ± 5.60; Ccr (before surgery) [mg/dL], 0.93 ±
0.18 and 0.89 ± 0.23; Ccr (after surgery) [mg/dL] 1.22 ±
0.34 and 0.89 ± 0.31; Clcr (before surgery) [mL/min] 92.43
± 26.68 and 100.60 ± 32.5; Clcr (after surgery) [mL/min]
80.97 ± 37.06 and 97.61 ± 27.80; eGFR(before surgery)
80.22 ± 18.11 and 83.59 ± 21.49; eGFR (after surgery)
64.96 ± 21.53 and 84.42 ± 27.04 in patients after TN
and NSS, respectively. The plasma concentration-
time profiles for paracetamol in the patients after
total nephrectomy and in the patients after nephron
sparing surgery are shown in Figure 1.
No significant differences were found in such
parameters as age, weight, height and BMI (Body
Mass Index) between both studied groups. In the TN
group low Ccr was observed in 1 patient. Low Clcr
and eGFR values were observed in 18 and 20
patients, respectively. High Clcr was observed in 1
patient. In the NSS group low Ccr values were
observed in 3 patients, whereas a high Ccr value was
observed in one patient. Low Clcr and eGFR values
were observed in 4 and 5 patients, respectively.
Table 1. Pharmacokinetic parameters for paracetamol in plasma.
Pharmacokinetic
TN NSS p value p value Gmean ratiob
parametersa
(n = 37) (n = 17) TN vs. male vs. (90% CI)
S ± SD S ± SD NSS female TN vs NSS
AUC5min-t (µg∑h/mL) 29.24 ± 13.86 34.85 ± 14.28 0.2896 0.0780
1.18
(0.94; 1.48)








2/mL) 115.47 ± 80.44 109.60 ± 54.46 0.6447 0.2590
1.01
(0.70; 1.45)
MRT5min-t (h) 2.98 ± 1.27 2.61 ± 0.67 0.2713 0.9127
0.92
(0.76; 1.12)
t1/2 (h) 2.34 ± 0.96 1.93 ± 0.50 0.1415 0.4673
0.87
(0.72; 1.05)
Cl (L/h) 41.04 ± 16.81 37.09 ± 25.69 0.7828 0.0173
0.85
(0.68; 1.06)
Cmax (µg/mL) 29.08 ± 17.39 27.54 ± 15.70 0.6692 0.5289
0.93
(0.71; 1.22)
Vd (L) 63.96 ± 25.51 59.91 ± 29.31 0.8667 0.0405
0.93
(0.75; 1.14)
a Arithmetic means ± standard deviations (CV%) are presented with CV (%) in the brackets. b Ratio of geometric means (Gmeans) between
groups with the lower and upper bounds of a 90% confidence interval in the brackets are presented.
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During the course of the research there were no seri-
ous or unexpected adverse events. The PK parame-
ters and a summary of the statistical analyses for
paracetamol are shown in Table 1.
The mean paracetamol Cmax was similar for
both the TN and NSS groups (29.08 ± 17.39 and
27.54 ± 15.70 µg/mL, respectively). There was no
significant difference between the groups under
analysis (p = 0.6692). There was no statistically sig-
nificant difference revealed for t1/2, but t1/2 in the
NSS group tended to be shorter than in the TN group
(1.93 ± 0.50 and 2.34 ± 0.96 h, respectively; p =
0.1415). There were no statistically significant dif-
ferences between the TN and NSS groups under
analysis for the following pharmacokinetic parame-
ters: AUC5min-t (p = 0.2896), AUC5min-inf (p = 0.6320),
AUMC5min-t (p = 0.1345), Vd (p = 0.8667), MRT5min-t
(p = 0.2713), and Cl (p = 0.7828). For all parameters
the confidence interval for ratio of geometric means
included the value of one which confirms the lack of
significant differences in absorption of paracetamol
between the TN and NSS groups in this study.
The two-way ANOVA revealed a significant
difference between men and women for Cl (p =
0.0173), AUMC5min-t (p = 0.0343), and Vd (p =
0.0405). A more detailed analysis within the treat-
ment groups revealed that the mean paracetamol
Cmax was similar in the TN group both in men and
women (29.05 ± 16.19 and 29.14 ± 19.95 µg/mL,
respectively; p = 0.9876). The systemic exposure of
paracetamol (AUC5min-inf) in men was lower than in
women (33.03 ± 16.70 and 41.73 ± 16.71 µg∑h/mL,
respectively). There was no statistically significant
difference between the groups under analysis (p =
0.1288). The AUMC5min-t in men was lower than in
women (40.10 ± 21.73 and 58.56 ± 28.71 µg∑h2/mL,
respectively). There was statistically significant dif-
ference between the groups under analysis (p =
0.0343). There were no statistically significant dif-
ferences between men and women in the TN group
under analysis for the following PK parameters:
AUC5min-t (p = 0.1013), Vd (p = 0.1621), t1/2 (p =
0.3886), and Cl (p = 0.0751).
The mean paracetamol Cmax in the NSS group
was lower in men than in women (22.27 ± 14.09 and
31.24 ± 16.40 µg/mL, respectively). There was no
statistically significant difference between the
groups under analysis (p = 0.2592). The systemic
exposure to paracetamol (AUC5min-inf) in men was
lower than in women (36.45 ± 21.94 and 43.17 ±
12.11 µg∑h/mL, respectively). There was no statisti-
cally significant difference between the groups
under analysis (p = 0.4279). The Vd value tended to
be higher in men than in women (102.28 ± 59.79
and 69.67 ± 28.57 L). There was no statistically sig-
nificant difference between the groups under analy-
sis (p = 0.2216). The Cl value tended to be higher in
men than in women (44.08 ± 36.63 and 24.65 ± 6.06
L/h, p = 0.2213). There were no statistically signifi-
cant differences between men and women in group
NSS under analysis for the following pharmacoki-
netic parameters: AUC5min-t (p = 0.4863), t1/2 (p =
0.8036), and AUMC5min-t (p = 0.5283).
A significant negative correlation was identi-
fied in the TN group between t1/2 and Clcr (r = 
-0.4293, p = 0.0322), and between MRT5min-t and Clcr
(r = -0.4271, p = 0.0332) . Correlations between t1/2
and other parameters of creatinine clearance were
not significantly different from zero eGFR (r = 
-0.11912, p = 0.5706), Ccr (r = -0.06879, p =
0.7439), as were the correlations between MRT5min-t
and eGFR (r = -0.08131, p = 0.6992) and Ccr (r = 
-0.1502, p = 0.4736). In the NSS group correlations
between t1/2 and Clcr (r = 0.3408, p = 0.2545), eGFR
(r = 0.3532, p = 0.2366), Ccr (r = -0.2204, p =
0.4693) and between MRT5min-t and Clcr (r = 0.1925,
p = 0.5286), eGFR (r = 0.1268, p = 0.6798), Ccr (r =
-0.0943, p = 0.7592) were not significantly different
from zero. 
DISCUSSION
Intravenous paracetamol (also known as acet-
aminophen) is one of the more commonly used anal-
gesics and antipyretics in intensive care units and
surgical departments. It guarantees a quick and effi-
cacious therapeutic effect and enables elimination of
differences resulting from individually varying rates
of absorption (9, 10). Comparing the early bioavail-
ability of rectal, effervescent oral and intravenous
paracetamol, only intravenous and effervescent
paracetamol were found in therapeutic concentra-
tions one day after surgery (11). 
A major benefit of intravenous administration
of paracetamol is the fact that the median time to
reach tmax is much faster than typically reported for
oral or rectal formulations (> 45 min) (4). Cmax,
which occurs at the end of a 15-minute infusion of
paracetamol, is up to 70% higher than that observed
with the same dose of oral acetaminophen, although
the overall exposure (area under the concentration
time curve) is very similar (12). 
However, caution must be used when adminis-
tering paracetamol to patients with liver dysfunc-
tion, active liver disease, alcoholism, chronic mal-
nutrition, severe hypovolemia (e.g., due to dehydra-
tion or blood loss), or severe kidney dysfunction
(i.e., creatinine clearance = 30 mL/min) (13).
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Despite its beneficial analgesic properties, some
data indicate that paracetamol induces cell death
with features of apoptosis in proximal tubular
epithelial cells (14) and elicits chronic long-term
renal toxicity (13).
As mentioned above, the harmful influence of
paracetamol is especially important in patients with
acute renal failure (15), where the elimination time
of paracetamol and its metabolites is longer (up to
three times slower elimination rate than in the con-
trol group). It has also been proved that when thera-
peutic doses of paracetamol are administered to
patients undergoing hemodialysis, t1/2 is reduced by
40-50%. Additionally, surgical removal of all or part
of the kidney may influence drug elimination,
because it: 1) reduces the number of active
nephrons, 2) alters permeability of capillaries (by
causing migration of fluids to extravascular areas)
and 3) causes hypoalbuminemia (by inducing local
inflammation) (16). 
There is no available data on the PK of para-
cetamol in nephrectomized patients. Therefore, this
study was designed to acquire information on how
strongly kidney resection (total or partial) may
influence the PK of intravenous administration of
paracetamol. 
After collecting blood samples (Fig. 1), we
observed similar time-dependent decreases in the
mean paracetamol plasma concentration in both
groups. While both types of nephrectomy cause a
decrease in renal function (by reducing either a
small or large amount of active nephrons), the plas-
ma concentration of paracetamol changes in a simi-
lar way. Data from the literature suggest that there
are structural and functional adaptations of the
remaining renal tissue, even at an early stage after
surgery (17). 
The plasma concentrations of paracetamol
(described above) in the TN and NSS groups were
similar and independent of gender. However, when
we compared AUMC5min-t, there was a significant
decrease in men in the TN group only. This effect
may have been induced by gender differences in
drug elimination (including body surface area, renal
blood flow, glomerular filtration, tubular secretion,
and tubular reabsorption) (18). However, as far as
paracetamol is concerned, data from the literature
are poor and inconsistent. In rats, large dosages of
paracetamol cause kidney necrosis, which is more
severe in young adult female rats (19). In elderly
patients, the elimination half-life is associated with
gender, since females have increased paracetamol
concentrations after intravenous paracetamol (20).
In accordance with our observations, previous data
showed that gender differences in drug clearance
were minor and not significant (21).
Another, more significantly altered parameter
is the elimination half-life of paracetamol. In the TN
group, it was similar to that reported in the literature
(approximately 2.24 to 3.30 h) (22) and was rela-
tively short. However, in several diseases like renal
failure (41.3 ± 2.2 h vs. 26.8 ± 1.1 h the half-life of
protein-derived acetaminophen-cysteine APAP-
CYS in patients with renal failure compared with
healthy controls, respectively) (23) or liver failure
(1.72 days) (24, 25), it is prolonged. Surprisingly,
our results indicated that t1/2 was shorter after NSS
than after TN (1.93 ± 0.50 vs. 2.34 ± 0.96 h, respec-
tively). These data suggest that the type of nephrec-
tomy is important in determining the half-life of
paracetamol. This observation could be helpful in
planning analgesic treatment after renal surgeries.
Further investigations are required to determine the
cause of these differences. 
CONCLUSIONS
Exposure to paracetamol was comparable in
both groups under analysis. The t1/2 after nephron
sparing surgery was shorter than after total nephrec-
tomy. Therefore, these patients may demand more
frequent drug administration. In the NSS group the
Cmax of the analgesic was considerably reduced in
men.
REFERENCES
1. Drozdzik M., Domanski L., Wojcicki J.,
Gawronska-Szklarz B., Machoy P. et al.: J.
Pharm. Pharmacol. 54 , 509 (2002).
2. Drozdzik M., Domanski L., Wojcicki J., Pudlo
A., Machoy P.: J. Clin. Pharmacol. 43, 524
(2003).
3. Jahr J.S., Lee V.K.: Anesthesiol. Clin. 28, 619
(2010).
4. Bertolini A., Ferrari A., Ottani A., Guerzoni S.,
Tacchi R. et al.: CNS Drug Rev. 12, 250 (2006).
5. Duggan S.T., Scott L.J.: Drugs 69, 101 (2009).
6. Hollenbeck B.K., Taub D.A., Miller D.C., Dunn
R.L., Wei J.T.: Urology 67, 254 (2006).
7. Uzzo R.G., Novick A.C.: J. Urol. 166, 6 (2001).
8. Brunner L.J., Bai S.: J. Chromatogr. B. Biomed.
Sci. Appl. 732, 323 (1999).
9. Chiam E., Weinberg L., Bellomo R.: Heart
Lung Vessel 7, 121 (2015).
10. Henrich W.L., Agodoa L.E., Barrett B., Bennett
W.M., Blantz R.C. et al.: Am. J. Kidney Dis. 27,
162 (1996).
The effect of total and partial nephrectomy on the pharmacokinetics... 935
11. HolmÈr Pettersson P., Hein A., ÷wall A.,
Anderson R.E., Jakobsson J.G.: Ambulatory
Surgery 12, 27 (2005).
12. Pasero C., Stannard D.: Pain Manag. Nurs. 13,
107 (2012).
13. McLaughlin J.K., Lipworth L., Chow W.H.,
Blot W.J.: Kidney Int. 54, 679 (1998).
14. Lorz C., Justo P., Sanz A., Subir· D., Egido J.
et al.: J. Am. Soc. Nephrol. 15, 380 (2004).
15. Fored C.M., Ejerblad E., Lindblad P., Fryzek
J.P., Dickman P.W. et al.: N. Engl. J. Med. 345,
1801 (2001).
16. Eyler R.F., Mueller B.A.: Nat. Rev. Nephrol. 7,
226 (2011).
17. Chapman D., Moore R., Klarenbach S., Braam
B.: Can. Urol. Assoc. J. 4, 337 (2010).
18. Soldin O.P., Mattison D.R.: Clin.
Pharmacokinet. 48, 143 (2009).
19. Mugford C.A., Tarloff J.B.: Toxicol. Lett. 93,
15 (1997).
20. Liukas A., Kuusniemi K., Aantaa R., Virolainen
P., Niemi M. et al.: Clin. Pharmacokinet. 50,
121 (2011).
21. Allegaert K., Olkkola K.T., Owens K.H., Van
de Velde M., de Maat M.M., Anderson B.J.:
BMC Anesthesiol. 14, 77 (2014).
22. Rawlins M.D., Henderson D.B., Hijab A.R.:
Eur. J. Clin. Pharmacol. 11, 283 (1977).
23. Curry S.C., Padilla-Jones A., OíConnor A.D.,
Ruha A.M., Bikin D.S. et al.: Med. Toxicol. 11,
169 (2015).
24. James L.P., Caparelli E.V., Simpson P.M.,
Letzig L., Roberts D. et al.: Clin. Pharmacol.
Ther. 84, 684 (2008).
25. James L.P, Letzig L., Simpson P.M., Capparelli
E., Roberts D.W. et al.: Drug Metab. Dispos.
37, 1779 (2009).
Received: 08. 03. 2016
